EricaLeighCampagnaroMD

PubMed

• 2 citations
  Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
  Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
  Blood Advances. 2025-03-11
• 1 citations
  Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis.
  Christy J Khouderchah, Madeleine Ochs, Matthew Pianko, Zahra Mahmoudjafari, Jordan Snyder
  Journal of Oncology Pharmacy Practice. 2024-09-01
• 2 citations
  Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
  Amro M Stino, Naresh Bumma, Rachel Smith, Long Davalos, Jeff Allen
  European Journal of Neurology. 2024-03-01

Abstracts/Posters

• Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
  Erica L. Campagnaro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018